About Us

Since 2016, Weill Cornell Medicine (New York) and the Gustave Roussy Cancer Campus (Paris) have joined forces to organize an annual conference that provides a forum for education, discussion, and networking among investigators interested in developing safe and effective RT-IT combinations (ImmunoRad).

Contact Info

Email
christine.corinus

Phone
+33 (0) 1 42 11 53 22

  Gustave Roussy Cancer Campus,
Research Department
Pièce 65 - B2M

 

Our story

The Immunorad international congress aims to provide a global vision of the problem. The first edition was held in 2016 at Gustave Roussy (Villejuif) and we invited colleagues from Cornell University (New York). From 160 participants three years ago, which was already unexpected, we increased to more than 430 this year. During these three days, we had the pleasant surprise that barely published data was presented, which is rare and demonstrates the desire of the speakers to exchange with fellow immunologists, radiotherapist oncologists and medical oncologists from around the world on this theme.

22th Sept 2016

1st EDITION Paris Fr

Expliquer l'émergence des traitements combinés d'immunothérapie et de radiothérapie pour lutter contre le cancer. L'idée était de réunir des experts mondiaux pour échanger des connaissances dans ces disciplines complémentaires.Promouvoir la collaboration entre chercheurs, cliniciens et industriels, en mettant l'accent sur l'impact de l'immunothérapie et des thérapies ciblées.
logo immunorad02

21th Sept 2017

2nd EDITION New York Us

The program offers two and one-half days of lectures, case presentations, and discussions on important topics such as modulating the tumor and host environment, immunological biomarkers for patient selection, and innovative clinical trial design.
logo immunorad02

20th Sept 2018

3st EDITION Paris Fr

An innovative meeting focusing on immunotherapy-radiotherapy combinations! The importance of immunology in tumor response to radiotherapy represents a major opportunity for our discipline. Novel therapies have emerged which target the immune cells. Combinations of such therapies to radiotherapy might translate into better local tumor control rates and also into better distant control given the possibility to use radiotherapy as an immunological enhancer of the anti-tumor immune response.
logo immunorad02

21th Sept 2019

4nd EDITION New York Us

currently being written
logo immunorad02


2020
2021

5th EDITION Paris Fr

COVID 19
Compte tenu des circonstances, la tenue de la conférence ne peut être maintenue.
logo immunorad02

22th Sept 2022

6th EDITION New York Us

Focal radiation therapy (RT) has attracted considerable attention as a combinatorial partner for immunotherapy (IT), largely reflecting a well-defined, predictable safety profile and at least some potential for immunostimulation. However, only a few RT-IT combinations have been tested successfully in patients with cancer, highlighting the urgent need for an improved understanding of the interaction between RT and IT in both preclinical and clinical scenarios.
logo immunorad02

27th SEPT 2023

7th EDITION Paris Fr

The clinical management of cancer is being revolutionized by agents that activate the immune system against the tumor. Nevertheless, many of these therapies benefit only to a minority of patients. In this context, radiotherapy is holding great promise as a means to complement immunotherapy in the management of malignant disorders. In particular, radiotherapy can generate an “in situ vaccination” effect that is at the foundation of optimal immune responses against cancer cells. Thus, the clinical potential of combining immunotherapy with radiotherapy is extraordinary. 
logo immunorad02

03th Oct 2024

8th EDITION New York Us

The clinical management of cancer is being revolutionized by agents that activate the immune system against the tumor. Nevertheless, many of these therapies benefit only a minority of patients. In this context, radiotherapy is holding great promises to complement immunotherapy in the management of malignant disorders. In particular, radiotherapy can generate an “in situ vaccination” effect that is at the foundation of optimal immune responses against cancer cells. Thus, the clinical potential of combining immunotherapy with radiotherapy is extraordinary. 
logo immunorad02

17th Sept 2025

9th EDITION Paris Fr

currently being written
Logo2025